Tail-Vein Experimental Metastasis Xenograft

Reagents and chemicals

• Sterile phosphate-buffered saline or another validated injection vehicle is used to suspend viable tumor cells for intravenous injection, and D-luciferin is used when firefly-luciferase-labeled cells are monitored by bioluminescence imaging^[1][2][5][6].

• Cell-culture medium, serum, trypsin or dissociation reagent, and cell-washing buffer are used to prepare single-cell suspensions before injection, and viability assessment is required because injected cell number and cell condition influence metastatic colonization efficiency^[1][2][3].

Antibodies, probes, dyes, or kits

• Firefly luciferase, fluorescent reporters, or dual luciferase reporters are used to label tumor cells for in vivo and ex vivo tracking, and H&E staining is used to confirm metastatic lesions in collected organs^[1][2][5][6].

• Immunohistochemistry or immunofluorescence markers may be used to verify tumor identity, proliferation, or pathway changes when the biological question requires tissue-level validation^[5][6][7].

Equipment and instruments

• Required equipment includes cell-culture instruments, hemocytometer or automated cell counter, viability-assay materials, syringes and needles suitable for mouse tail-vein injection, animal warming equipment when used to dilate the tail vein, an in vivo bioluminescence imaging system for luciferase models, and necropsy and histology equipment for endpoint confirmation^[1][2][5][6].

Preparation Steps

• Use immunodeficient mice for human xenograft cells and strain-compatible immunocompetent mice for syngeneic tumor cells; examples include luciferase-labeled MDA-MB-231 human breast cancer cells injected into NOD-SCID mice, inflammatory breast cancer cells injected into immunodeficient mice, and luciferase-expressing Lewis lung carcinoma cells injected into syngeneic C57BL/6 mice^[1][2][5][6].

• Prepare tumor cells as a single-cell suspension, remove clumps, determine cell concentration and viability, and keep injection conditions consistent across groups because cell handling, cell number, recipient animals, and injection technique contribute to variability in metastatic colonization assays^[1][3].

Operation Steps

• Inject tumor cells intravenously through the lateral tail vein using the cell number and volume validated for the selected cell line and mouse strain; published examples include MDA-MB-231 experimental lung-colonization models, inflammatory breast cancer brain-metastasis models, Lewis lung carcinoma intravenous models, and small-cell lung cancer xenograft models with organ-specific colonization differences^{[1][2][5][6][8]}.

• After injection, monitor animals longitudinally by bioluminescence imaging when luciferase-labeled cells are used, and collect organs at a predefined endpoint or humane endpoint for ex vivo imaging, gross lesion counting, histology, or molecular assays^[1][2][5][6].

• For studies comparing tumor-cell-intrinsic regulators, manipulate tumor cells before injection and inject equal viable cell numbers across groups; for studies of host microenvironmental regulators, compare matched recipient mouse genotypes or treatments using the same injected tumor-cell preparation^[1][3][7].

Data Acquisition and Analysis

• Interpret increased bioluminescent signal, increased metastatic nodule number, higher histologic tumor burden, or shortened survival as increased metastatic colonization, but avoid concluding that the tested factor regulates primary tumor invasion or intravasation because tail-vein injection bypasses those steps^[1][2][3][4].

• Use vehicle-injected animals when needed to distinguish procedure-related findings from tumor-cell colonization, use a known colonizing cell line as a positive model-control when establishing the assay, randomize animals before injection, and blind endpoint scoring when feasible because experimental metastasis assays are sensitive to injection quality, cell number, and endpoint measurement method^[1][3].

Problem: Lung or organ metastasis is absent or highly variable.

• Possible Cause: Injected cell number, cell viability, cell-line colonization capacity, host strain, or injection quality is not matched to the model.
• Literature-supported Solution: Pilot the cell number and endpoint for the specific tumor cell line and mouse strain, and standardize cell handling and tail-vein injection technique because these variables are identified as major contributors to experimental-metastasis variability^[1][3][6].

Problem: Bioluminescence signal does not match histologic tumor burden.

• Possible Cause: Reporter expression, substrate delivery, tissue depth, fur pigmentation, or lesion distribution can affect imaging signal.
• Literature-supported Solution: Confirm imaging results with ex vivo organ imaging and histology because protocol studies use bioluminescence for longitudinal monitoring and histologic evaluation for endpoint validation^[1][2][5][6].

Problem: The study question concerns early metastatic steps, but the tail-vein model gives a positive result.

• Possible Cause: Tail-vein injection bypasses primary tumor growth, invasion, and intravasation.
• Literature-supported Solution: Pair tail-vein experimental metastasis with an orthotopic or spontaneous metastasis model when testing mechanisms that may act before vascular dissemination^[2][3][4].